



## Antinuclear and Antiphospholipid Autoantibodies in Patients with peripheral Arterial Occlusive disease

*Knut Kroeger, Hamid Mouradi, Ernst Kreuzfelder, Gottfried Rudofsky, and Hans Grosse-Wilde*

### DISCLAIMER

The initial version of *ARD Online First* articles are papers in manuscript form that have been accepted and published in *ARD Online* but they have not been copy edited and not yet appeared in a printed issue of the journal. Copy editing may lead to differences between the *Online First* version and the final version including in the title; there may also be differences in the quality of the graphics. Edited, typeset versions of the articles may be published as they become available before final print publication.

Should you wish to comment on this article please do so via our eLetter facility on *ARD Online* (<http://ard.bmjournals.com/cgi/eletter-submit/ard.2004.022145v1>)

### DATE OF PUBLICATION

*ARD Online First* articles are citable and establish publication priority. The publication date of an *Online First* article appears at the top of this page followed by the article's unique Digital Object Identifier (DOI). These articles are considered published and metadata has been deposited with PubMed/Medline.

### HOW TO CITE THIS ARTICLE

*Kroeger K, Mouradi H, Kreuzfelder E, et al Antinuclear and Antiphospholipid Autoantibodies in Patients with peripheral Arterial Occlusive disease Ann Rheum Dis Published Online First [date of publication]\*. doi: 10.1136/ard.2003.022145*

\*Replace with date shown at the top of this page - remove brackets and asterisk

Online First articles are posted weekly at <http://ard.bmjournals.com/onlinefirst.shtml>

## **Antinuclear and Antiphospholipid Autoantibodies in Patients with Peripheral Arterial Occlusive Disease**

**K. Kröger,  
H. Mouradi,  
E. Kreuzfelder\*,  
G. Rudofsky,  
H. Grosse-Wilde\*,  
Department of Angiology,  
Institute of Immunology\*,  
University of Essen,  
Germany**

Correspondence:

Knut Kröger, MD  
Department of Angiology  
University Hospital Essen  
Hufelandstrasse 55  
45122 Essen  
Germany  
Tel.: +49 201 723 2230  
Fax: +49 201 723 5967  
e-mail: [knut.kroeger@uni-essen.de](mailto:knut.kroeger@uni-essen.de)

Referring to the Chapel Hill Consensus Conference, large peripheral arteries are only affected by giant cell vasculitis and in rare cases by polyarteritis nodosa (4,5). Vasculitis manifest via involvement of typical organs (lung, kidney, skin) or elevated C-reactive protein (CRP) level or erythrocyte sedimentation rate (ESR). Thus, a specific diagnostic effort to exclude vasculitis as an underlying disease in peripheral arterial occlusive disease (PAOD) patients might be unnecessary. On the other hand, there is increasing evidence that humoral immunity may play a role in the pathogenesis of atherosclerosis (1,2,9). Antinuclear antibodies were reported in 70 % of patients with severe coronary heart disease (CHD), compared to only 17 % in the control group (3). Thus, we prospectively studied the importance of autoantibody determination in patients symptomatic with PAOD.

695 patients (mean age  $\pm$  SD:  $68 \pm 10$  years) referred for interventional treatment of PAOD from 1998 to 1999 were included. In 118 PAOD-patients ( $61 \pm 12$  years) with a low atherosclerotic risk profile, or with rarefied distal arteries without media calcinosis, or with elevated ESR or CRP independent from local infections, the following autoantibodies were determined: antinuclear antibodies (ANA) by indirect immunofluorescence technique; antibodies against extractable nuclear antigens (ENA: SCL 70, RNP, SS-A, SS-B, Jo1, SM) by Western-blot; double-stranded DNA antibodies (ds-DNA), antineutrophil cytoplasmatic antibodies (c- and p-ANCA), antiphospholipid antibodies [cardiolipin, phosphatidylserine (APSA) and beta-2-glykoprotein] by enzyme linked immunoassay. In order to stratify the importance of autoantibody determination all patients with increased autoantibody concentration were clinically and sonographically followed up ( $24 \pm 6$  months) for evidence of vasculitides or collagen disease. A multivariate logistic regression analysis was performed to evaluate the importance of CRP and ESR in patients with autoantibody concentrations above the appropriate reference value.

38 out of the 121 patients had increased autoantibody concentrations (Tab. 1). ANA were the most frequent autoantibodies detected in 14 patients followed by APSA in 11, and anti-beta-2-glycoprotein antibodies in 12. Patients with increased autoantibody concentration were not different in PAOD stages and affected segments, but in patients with increased autoantibody concentrations the rate of elevated ESR was higher ( $p = 0.0043$ ). Increased 2 hours ESR was associated with an odds ratio of 7.1 (95%-CI: 1.49 – 33.81) in determination of increased

autoantibody concentrations. During follow-up of  $24 \pm 6$  months no vasculitides or collagen diseases could be detected by clinical examination and in part by nail fold capillary microscopy, pulmonary or gastrointestinal imaging in the 38 patients.

The analysed population of 121 PAOD patients is an individually selected group out of all PAOD patients, but represent those patients in whom we are confronted with the question for vasculitis. Elevated concentrations of autoantibodies were not a rare finding in the investigated patients. Increased autoantibody concentrations significantly correlated with elevated ESR. Our data are the first to report the results of autoantibody determination in a larger population of patients suffering from PAOD. In contrast to the high rate of ANA in patients with coronary atherosclerosis (3,7,8), the prevalence of ANA in our PAOD patients was much lower. Whether this different prevalence of ANA was due to different extensions of atherosclerosis, or due to specific differences in coronary and peripheral manifestations can only be speculated. In agreement with the coronary studies, no association of the determined autoantibodies with the classical risk factors was found. The higher rate of elevated ESR in the patients with increased autoantibody concentrations might be associated with a higher degree of inflammatory activity of the atherosclerosis. Antiphospholipid and beta-2-glykoprotein antibodies which are most relevant in association to atherosclerosis did not seem to be of prognostic impact (6,7,8), but antibody determination in larger groups of non-selected patients is desirable.

## References:

1. Farhey Y, Hess EV. Accelerated atherosclerosis and coronary disease in SLE. *Lupus* 1997;6:572-577
2. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. *Immunol Res* 1996;15:315-322
3. Grainger DJ, Bethell HWL. High titres of serum antinuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. *Ann Rheum Dis* 2002;61:110-114
4. Hunder GG, Arend WP, Bloch DA, Calabrese JH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot jr, Masi AT, McShane DJ, Michel BA, Mills JA, Stevens MB, Wallace SL, Zvaifler NU. The American College of Rheumatology 1990 criteria for classification of vasculitis. *Arthritis Rheum* 1990;33:1065-1067
5. Jennette CJ, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffmann GS, Hunder GG, Kallenberg SGM, McCluskey RT, Sinico RA, Ree AJ, van Es LA, Waldher R, Wiik A: Nomenclature of systemic vasculitides: proposal of an international consensus conference. *Arthritis Rheum* 1994;37:187-192
6. Limaye V, Beltrame J, Cook R, Gillis D, Pile K. Evaluation of antibodies to beta2-glycoprotein-I in the causation of coronary atherosclerosis as part of the antiphospholipid syndrome. *Aust N Z J Med* 1999;29:789-93
7. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ, Harats D, George J, Levy Y, Peter JB, Motro M, Shoenfeld Y. Coronary artery diseases but not coronary calcification is associated with elevated levels of cardiolipin, beta-2-glycoprotein-I and oxidized LDL antibodies. *Cardiology* 2001;95:20-24
8. Sherer Y, Tenenbaum A, Praprotnik S, Shemesh J, Blank M, Fisman EZ, Motro M, Shoenfeld Y. Autoantibodies to cardiolipin and beta-2-glycoprotein-I in coronary artery disease patients with and without hypertension. *Cardiology* 2002;97:2-5
9. Wick G, Schett G, Amberger A, Setitz CS, Michaelis D, Metzler B. Is atherosclerosis an immunologically mediated disease? *Immunol Today* 1995;16:27-33

	No Autoantibody Determination	Autoantibody Determination	
		No Increased Autoantibodies	Increased Autoantibodies
<b>Number</b>	577	83	38
<b>Age (mean <math>\pm</math> SD)</b>	68 $\pm$ 10 years	61 $\pm$ 12 years	59 $\pm$ 14 years
<b>PAOD stage II</b>	74 %	63 %	58 %
<b>Stage III</b>	5 %	4%	9 %
<b>Stage IV</b>	21 %	33 %	33 %
<b>Segment of vascular lesions:</b>			
<b>Crural</b>	8 %	22 %	24 %
<b>Femoral</b>	41 %	30 %	31 %
<b>Iliacal</b>	9 %	5 %	8 %
<b>Combined</b>	42 %	43 %	37 %
<b>Risk factors:</b>			
<b>Diabetes mellitus</b>	37 %	26 %	10 %
<b>Hypertension</b>	50 %	39 %	30 %
<b>Dyslipoproteinemia</b>	66 %	41 %	28 %
<b>Nicotine abuse</b>	75 %	27 %	35 %
<b>Markers of inflammation</b>			
<b>1. h BSR &gt; 20 mm</b>	31 %	29 %	61 %*
<b>2. h BSR &gt; 40 mm</b>	32 %	30 %	61 %*
<b>CRP &gt; 1 mg/dl</b>	20 %	37 %	50 %
<b>History of CHD</b>	47 %	17 %	16 %

Tab. 1: Given are the characteristics of those patients no autoantibodies were determined in, those patients autoantibodies were determined in, but not increased, and those with increased autoantibodies. Frequencies of variables are expressed in per cent of the number of patients in each group. \*  $p = 0.0043$  versus "no measured autoantibodies"



## Antinuclear and Antiphospholipid Autoantibodies in Patients with peripheral Arterial Occlusive disease

Knut Kroeger, Hamid Mouradi, Ernst Kreuzfelder, Gottfried Rudofsky and Hans Grosse-Wilde

*Ann Rheum Dis* published online April 28, 2004

---

Updated information and services can be found at:  
<http://ard.bmj.com/content/early/2004/04/28/ard.2004.022145.citation>

---

*These include:*

### **Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

---

### **Notes**

---

To request permissions go to:  
<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:  
<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:  
<http://group.bmj.com/subscribe/>